Business Wire

BSMO

1.2.2021 01:32:14 CET | Business Wire | Press release

Share
Notice Regarding Business Alliance With BSMO Co., Ltd. and SBI Africa Co., Ltd.

BSMO Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative Director: Tadashi Shimizu, hereinafter "BSMO") has announced today that BSMO has entered into a business alliance agreement with SBI Africa Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative Director: Tomoya Kitagawa, hereinafter "SBI Africa").

1. Background

As a pioneer in the field of SNS marketing, BSMO, through the best use of D2C x SNS marketing expertise and technology, provides one-stop growth hacking services for D2C e-commerce companies and helps deliver high-quality Japanese products and services to the world.

The population of Africa, where many emerging countries are located, is expected to double from 1.06 billion in 2019 to 2.11 billion people in 2050, according to the latest United Nations projections.

With the rapid population growth and economic growth in the African countries, the automobile usage rate is increasing every year which is driving a strong demand for reliable and affordable used cars from Japan.

By forming a business alliance with SBI Africa, which exports Japanese used cars to emerging countries, BSMO will introduce its D2C x SNS marketing expertise and technology to the SBI Group in order to strengthen the D2C exports in Africa, and thus improve the profitability and corporate values of both parties.

2. Details of the Business Alliance

(1) Improving the quality of SBI Africa's products and services by providing marketing research, advertising strategies, measurement strategies, design strategies, AI analytics, operations services and customer support services.
(2) Improving the profitability and brand value of both parties in the African region through joint sales of BSMO affiliated products and services on SBI Africa’s cross-border e-commerce website.
(3) Jointly providing system development and marketing strategy services for Japanese companies operating in Africa.
(4) Improving the profitability of BSMO and the marketing capabilities of SBI Group, through BSMO’s introduction of its marketing expertise and technology to SBI Group, etc.

[Company Overview]

Name

BSMO Co., Ltd.

Location

1-17-1 Toranomon, Minato-ku, Tokyo Toranomon Hills Business Tower 14th floor

Representative

Tadashi Shimizu

Business Description

D2C marketing business, global growth hack business using SNS, branding business, media business, system development business, artificial intelligence (AI) development business, etc.

Name

SBI Africa Co., Ltd.

Location

1-6-1 Roppongi, Minato-ku, Tokyo Izumi Garden Tower 15F

Representative

Tomoya Kitagawa

Business Description

Overseas export business of domestic used cars, financial service provision business in partnership with overseas financial institutions, venture capital investment targeting the African region, etc.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye